Efavirenz induces alterations in lipid metabolism through AMPK activation by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Efavirenz induces alterations in lipid metabolism through AMPK 
activation
A Blas-García*1, D Ballesteros2, D Monleón1, JM Morales1, M Rocha1, 
VM Víctor1, N Apostolova3 and JV Esplugues3
Address: 1University of Valencia, Valencia, Spain, 2Fundacion Juan Esplugues, Valencia, Spain and 3CIBERehd-University of Valencia, Valencia, 
Spain
* Corresponding author    
Background
Recent evidence suggests that the NNRTI efavirenz (EFV)
contributes to changes in lipid and body fat composition
that are implicated in lipoatrophy. As the liver is an
important organ in lipid metabolism, we have evaluated
the effects of clinically-used concentrations of EFV on
mitochondrial function and cellular lipid metabolism in
vitro, and the implication of AMP-activated protein kinase
(AMPk), the master switch for regulation of cellular
bioenergetics, in these processes.
Methods
O2 consumption in non-HIV infected Hep3B cells was
measured with a Clark-type electrode. Following incuba-
tion (1 hr) with EFV (10, 25 or 50 μM), intracellular ATP
was measured by fluorescence, mitochondrial membrane
potential (Δψm), indicative of mitochondrial function,
was analyzed by static cytometry, and AMPK was evalu-
ated by Western blotting. In order to further study the
implication of this enzyme, selected experiments were
performed in cells pretreated (30 min) with the AMPK
inhibitor Compound C (20 μM). The expression of the
fatty acid transporter CD36 was analyzed by PCR, and the
intracellular lipid content was determined by nuclear
magnetic resonance (NMR) after 4 hr incubation with
EFV.
Summary of results
EFV produced an immediate reduction of mitochondrial
function, evident by the significant and dose-dependent
inhibition of mitochondrial O2 consumption and the
decrease of intracellular ATP and Δψm. This metabolic
stress promoted the activation of AMPK, triggering several
of its signalling pathways, as EFV induced an increment in
CD36 mRNA expression and in intracellular lipid content,
which could have been a result of the formation of lipid
droplets. This intracellular lipid increase was not present
in cells treated with Compound C, which points to a key
role for AMPK in these mechanisms.
Conclusion
Given that EFV treatment is usually prolonged, these
mechanisms may effect the general regulation of lipid
metabolism and could cause the alterations that are char-
acteristic of lipoatrophy.
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